Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US
'Both Markets Require Rigorous Standards For Approval'
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
You may also be interested in...
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.